These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 16489035)

  • 1. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
    Yan H; Frost P; Shi Y; Hoang B; Sharma S; Fisher M; Gera J; Lichtenstein A
    Cancer Res; 2006 Feb; 66(4):2305-13. PubMed ID: 16489035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetaldehyde promotes rapamycin-dependent activation of p70(S6K) and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human neuroblastoma cells.
    Fang CX; Yang X; Sreejayan N; Ren J
    Exp Neurol; 2007 Jan; 203(1):196-204. PubMed ID: 16962100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
    Ly C; Arechiga AF; Melo JV; Walsh CM; Ong ST
    Cancer Res; 2003 Sep; 63(18):5716-22. PubMed ID: 14522890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
    Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S
    Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.
    Frost P; Shi Y; Hoang B; Lichtenstein A
    Oncogene; 2007 Apr; 26(16):2255-62. PubMed ID: 17016437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
    Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
    Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
    Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability.
    Beugnet A; Tee AR; Taylor PM; Proud CG
    Biochem J; 2003 Jun; 372(Pt 2):555-66. PubMed ID: 12611592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
    Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.
    Tirado OM; Mateo-Lozano S; Notario V
    Oncogene; 2005 May; 24(20):3348-57. PubMed ID: 15782132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001.
    Baumann P; Hagemeier H; Mandl-Weber S; Franke D; Schmidmaier R
    Anticancer Drugs; 2009 Apr; 20(4):259-66. PubMed ID: 19240643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
    Hidalgo M; Rowinsky EK
    Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
    Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
    Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma.
    Wan X; Mendoza A; Khanna C; Helman LJ
    Cancer Res; 2005 Mar; 65(6):2406-11. PubMed ID: 15781656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced radiation damage of tumor vasculature by mTOR inhibitors.
    Shinohara ET; Cao C; Niermann K; Mu Y; Zeng F; Hallahan DE; Lu B
    Oncogene; 2005 Aug; 24(35):5414-22. PubMed ID: 15940265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.
    Mungamuri SK; Yang X; Thor AD; Somasundaram K
    Cancer Res; 2006 May; 66(9):4715-24. PubMed ID: 16651424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
    Jernberg-Wiklund H; Nilsson K
    Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.
    Gu L; Gao J; Li Q; Zhu YP; Jia CS; Fu RY; Chen Y; Liao QK; Ma Z
    Leukemia; 2008 Nov; 22(11):2091-6. PubMed ID: 18685609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.